Michael Lassmann1, Dietmar Nosske. 1. Department of Nuclear Medicine, University of Würzburg, 97080 Würzburg, Germany. lassmann@nuklearmedizin.uni-wuerzburg.de
Abstract
PURPOSE: (223)Ra-Chloride (also called Alpharadin®) targets bone metastases with short range alpha particles. In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using (223)Ra-chloride. The purpose of this work was to provide a comprehensive dosimetric calculation of organ doses after intravenous administration of (223)Ra-chloride according to the present International Commission on Radiological Protection (ICRP) model for radium. METHODS: Absorbed doses were calculated for 25 organs or tissues. RESULTS: Bone endosteum and red bone marrow show the highest dose coefficients followed by liver, colon and intestines. After a treatment schedule of six intravenous injections with 0.05 MBq/kg of (223)Ra-chloride each, corresponding to 21 MBq for a 70 kg patient, the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to the red bone marrow is approximately 1.5 Gy. CONCLUSION: The comprehensive list of dose coefficients presented in this work will assist in comparing and evaluating organ doses from various therapy modalities used in nuclear medicine and will provide a base for further development of patient-specific dosimetry.
PURPOSE: (223)Ra-Chloride (also called Alpharadin®) targets bone metastases with short range alpha particles. In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using (223)Ra-chloride. The purpose of this work was to provide a comprehensive dosimetric calculation of organ doses after intravenous administration of (223)Ra-chloride according to the present International Commission on Radiological Protection (ICRP) model for radium. METHODS: Absorbed doses were calculated for 25 organs or tissues. RESULTS: Bone endosteum and red bone marrow show the highest dose coefficients followed by liver, colon and intestines. After a treatment schedule of six intravenous injections with 0.05 MBq/kg of (223)Ra-chloride each, corresponding to 21 MBq for a 70 kg patient, the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to the red bone marrow is approximately 1.5 Gy. CONCLUSION: The comprehensive list of dose coefficients presented in this work will assist in comparing and evaluating organ doses from various therapy modalities used in nuclear medicine and will provide a base for further development of patient-specific dosimetry.
Authors: S Nilsson; P Strang; A K Aksnes; L Franzèn; P Olivier; A Pecking; J Staffurth; S Vasanthan; C Andersson; Ø S Bruland Journal: Eur J Cancer Date: 2012-02-15 Impact factor: 9.162
Authors: Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland Journal: Clin Cancer Res Date: 2005-06-15 Impact factor: 12.531
Authors: Robert F Hobbs; Hong Song; Christopher J Watchman; Wesley E Bolch; Anne-Kirsti Aksnes; Thomas Ramdahl; Glenn D Flux; George Sgouros Journal: Phys Med Biol Date: 2012-05-01 Impact factor: 3.609
Authors: Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag C Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland Journal: Lancet Oncol Date: 2007-07 Impact factor: 41.316
Authors: Vivek Subbiah; Pete M Anderson; Kalevi Kairemo; Kenneth Hess; Winston W Huh; Vinod Ravi; Najat C Daw; Neeta Somaiah; Joseph A Ludwig; Robert S Benjamin; Sant Chawla; David S Hong; Funda Meric-Bernstam; Gregory Ravizzini; Eugenie Kleinerman; Homer Macapinlac; Eric Rohren Journal: Clin Cancer Res Date: 2019-02-07 Impact factor: 12.531
Authors: Thorsten D Poeppel; Daria Handkiewicz-Junak; Michael Andreeff; Alexander Becherer; Andreas Bockisch; Eva Fricke; Lilli Geworski; Alexander Heinzel; Bernd J Krause; Thomas Krause; Markus Mitterhauser; Wilfried Sonnenschein; Lisa Bodei; Roberto C Delgado-Bolton; Michael Gabriel Journal: Eur J Nucl Med Mol Imaging Date: 2017-12-12 Impact factor: 9.236
Authors: Calvin N Leung; Brian S Canter; Didier Rajon; Tom A Bäck; J Christopher Fritton; Edouard I Azzam; Roger W Howell Journal: J Nucl Med Date: 2019-09-13 Impact factor: 10.057